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Summary 
The Brazilian legislation did not recognize pharmaceutical patents for products and processes 
up until 1996, an exemption which started in 1945 for products and 1969, for processes. In this period, 
the domestic companies freely reproduced medicines developed by large companies from abroad and 
commercialized them in the local market with their own trademarks. They applied considerable efforts 
and resources in marketing, aiming to consolidate their brands next to the medical class, but they did 
not had to face the costs of research and development (R&D). This strategy guaranteed a considerable 
profitability for the domestic laboratories, but it was made impracticable by the new institutional 
landmark that emerged after the regulation of the Patents Law (“Lei de Propriedade Intelectual” – 
number 9.279 of 05/14/1996) and the Generic Medicines Law (“Lei do Medicamento Genérico” – 
number 9.787 of 02/10/1999). This article illustrates, through analysis based on information obtained 
from secondary sources, interviews and a Panel of Specialists, how the new competitive environment 
forced the companies to adopt a new strategic position, in which innovation gained importance. 
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1. Introduction 
This article aims to discuss the changes occurred in the Brazilian institutional plan and how they 
modified the interactions between the actors of the Brazilian pharmaceutical industry, creating perhaps 
new elements towards an indigenous sectoral system of innovation. It stresses the role of domestic 
companies1, and so because they were much more affected by the new regime established after 1996, 
with the Patents Law (“Lei de Propriedade Intelectual” – number 9.279 of 05/14/1996) and the Generic 
Medicines Law (“Lei do Medicamento Genérico” – number 9.787 of 02/10/1999) and created a new 
competitive environment that forced companies to new understandings of their position and their 
possibilities.  
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The article is composed of this Introduction, three development topics and the conclusions. The 
second topic congregates the methodological procedures, the third recoups literature on Institutional 
Economy, with distinction to the way the institutions create and regulate the ongoing activities, as well 
as new patterns of behavior. 
The fourth section presents the main alterations occurred in the Brazilian economic-institutional 
plan recently, the consequent emergency of a new competitive environment in the Brazilian 
pharmaceutical industry and the positioning of the companies in this new system. We present the 
reconfiguration of the sector after the emergence of generic medicines, associated to an increasing 
share of domestic firms in the local market. The perspectives associated to the sale of these medicines 
stimulated the entrance of foreign laboratories and investments in expansion and modernization on the 
part of already established companies. Moreover, the paper assembles examples of how innovation, 
even though punctual and incremental, starts to be incorporated as an element re-defining competition, 
in great measure because, in the scenario imposed by the institutional changes, the perspectives offered 
to domestic firms and their traditional way of life is to produce unprotected copies. On a rather reduced 
space, or to innovate. 
Finally, the conclusions of the paper point out that, in the existence of an institutional 
framework stimulating innovation, the Brazilian pharmaceutical industry seems to direct efforts in 
research, development and innovation (RD&I), focusing on the creation of new abilities, indispensable 
to the survival of companies in the new context. Despite incipient, this process of search for innovation 
in the Brazilian pharmaceutical industry deserves to be studied. Will it be that the new elements allow 
us to speak of a new trajectory? The paper presents elements supporting this claim, but they are far 
from unambiguous, and much is yet to be done in order to create a really new environment and an 
associate dynamics, deserving to be named a sectoral system of innovation. 
2. Methodological procedures 
The analysis carried out here was based on secondary and primary sources. The first ones 
comprehend the papers based on already edited pieces about the study subject, as dissertations, 
theses, articles and documents presented in symposiums and academic congresses. Additionally, a 
great number of information, for the 2000-2007 period, was collected on companies’ websites, the 
“Organização Pró-Genérico” website, publication Innovation UNICAMP, Brazilian business 
newspapers “Valor Econômico” and “Gazeta Mercantil”, Sectorial BNDES, amongst 
complementary others. 
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Carmo & Blacksmith (1998) point out that the use of periodical article as information 
source allows the gathering of raw data on a given social phenomenon and to disclose the impact 
that given type of information has on the segments of opinion. However, it was necessary to 
consider that the information spread through these channels is constructed, frequently, based on 
market rationalities and logics or diffusion of self-interests. 
With the objective of filtering, to compare and to legitimize the data obtained from 
secondary sources, as well as validating the hypothesis of the existence of a new institutional 
paradigm in the Brazilian pharmaceutical sector and elucidating the main opportunities and 
challenges that it represents, the study made use of material collected from interviews and also from 
a panel of specialists. This panel had the format of a technical Meeting, entitled “Science, 
Technology and Innovation and the Development of the Pharmaceutical System of Innovation: the 
Future of the Brazilian Pharmaceutical Industry” and congregated twenty two participants, amid 
professors and academics, professional researchers from the R&D area of Brazilian pharmaceutical 
laboratories, and graduate students. 
The contributions of Gavigan & Scarpolo (1999) and those of Miles, Keenan & Kaivo-Oja 
(2002) were important for the choice of this methodological tool. The first authors argue that these 
panels, even though not seen as a ‘methodology’ itself, show an important complement to the 
employed methodology. The second authors point out that panels of specialists are useful in topics 
that reveal complexity and which contain uncertainty on the data or of its interpretation. 
3. A revision of the institutionalist approach  
All the historical experiences of supported economic growth – since at least the First Industrial 
Revolution – have found the conditions that made them possible inside a set of institutions, common 
norms of behavior and public policies (Cimoli, Dosi, Nelson, & Stiglitz., 2007). The institutionalist 
approach is inter-disciplinary, gaining influence of politics, sociology, psychology and factors related 
to other sciences. The inclusion of the institutions into the analysis of the movement of changes helps 
to contemplate the construction of a theoretical framework which explains the development of 
trajectories taking in account the technological patterns and their pathways, always in agreement with 
the social, political, scientific and institutional environment, in one determined historical period 
(HODGSON, 1998). 
For Coriat & Weinstein (2004) it is the institutional norms, routines, common habits, 
established practices, rules, laws and patterns of behavior of the institutions that mold the action of the 
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agents and affect their interactions. The authors point out that the influence of the institutions on 
individual actions provides some stability to the socioeconomic systems, in part for restricting the 
diverse and changeable actions of the agents. Coriat & Weinstein (2002) suggest classifying the 
institutions in two types, noting that both contribute to the definition and the setting of ‘game rules’ for 
the individual agents: (i) institutions that include a dimension of explicit coercion, imposed on all 
agents. This dimension is guaranteed by a system of penalties, fruit of a complex social apparatus that 
imposes operational rules and assure its fulfillment; (ii) institutions related to the rules that individual 
agents decide ‘to impose’ on themselves, such as the relations that bind them, the standards they decide 
to follow – by contracts, conventions or rules established by the agents. 
The second type of institutions is complementary to the first ones and this is the reason why the 
institutions establish the limits and the autonomy of the agents when it comes to the initiative margin 
they can enjoy in their private arrangements. This double dimension of ‘coercion’ and ‘freedom’ is 
crucial to understand the ways through which the institutions operate and mold the behavior of the 
agents. 
When implementing new environments, some institutions open new fields of activity where the 
agents will be capable of developing their abilities. Many key economic institutions have to be 
analyzed in the perspective of creating new activities. And these types of ‘constituting rules’ create new 
positions and new types of behavior (CORIAT & WEINSTEIN, 2004). For example, the incorporation 
of the environmentalist guideline went from an almost complete heresy to the condition of dominant 
strategic paradigm in the chemical and petrochemical industries, and that was so as a reflection of 
activist manifestations and changes in the pertinent legislations (HOFFMAN, 2001). 
Nelson and Winter (1982) state that the organizations make use of ‘routines’ that are developed 
and susceptible to alteration, however in gradual form, adapting to changes in the existing conditions. 
In other words, the routines have to be endowed with some permanence and stability, which does not 
mean necessarily rigidity – equivalent to the relative stability of a genome. In such a way, the actions 
that show results tend to be incorporated in the form of new routines – which would correspond to 
advantageous mutations, incorporated to the genome as adaptation advantages. 
Newman (2000) observes that, in certain occasions, changes in the institutional plain have direct 
impact in the process of routines internalization. However, this process of learning and adaptation is 
frequently slow and gradual, since new abilities are difficult to create and cost worthy to modify, over 
all the ones related to the old ‘behaviors’. 
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3.1. A systemic approach 
An important contribution of the institutionalist approach of the innovation process is to clearly 
indicate the existence of national trajectories of innovation, which are widely determined by the social 
context in which various agents operate. Firms have prominent roles, but they are embedded, deeply 
rooted, in a broader context.  
Neoschumpeterian economists Freeman (1988) and Lundvall (1992) developed the concept of 
‘innovation systems’ to explain different competitiveness degrees of economies, especially for the 
technological competitiveness and the abilities to innovate. The National System of Innovation (NIS) 
comprehends all the actors and institutions involved in scientific and technological activities, which 
contribute to the development, introduction, diffusion and use of innovations. It includes, of course, the 
firms, but also the university system, research centers, laboratories of R&D and other agents of the 
public and private sectors, not necessarily explicitly related to science and technology. The NISs are 
based on the idea that many of the factors that influence the innovation activities are national. At the 
same time, it is also clear that the innovation processes are, in many ways, international, therefore 
technologies and knowledge circulate between borders, local companies interact with foreign 
companies and universities. Moreover, many markets, in terms of companies and it’s the competition 
processes, are global. 
It is possible to split the National System of Innovation in different sectors, because the 
characteristics of the technological progress and the flow of scientific information varies considerably 
across industries (PAVITT, 1984). The innovation processes vary from sector to sector in terms of 
development, rate of technological change, interactions and knowledge access, as well as in terms of 
organizational structures and institutional factors. Thus, Sectoral Systems of Innovation (SSI) emerge, 
formed by heterogeneous groups of agents who interact to generate, adopt and use technologies – novel 
or mature – and for the creation, production and use of products pertinent to each of the sectors in 
question (NELSON, 2006). To support the existence of SSIs is equivalent to recognize that the national 
and regional borders can vary and that almost always in accordance with the analyzed sector. The idea 
is to complement the notion of SNI, delimited in its strict direction by national borders (MALERBA, 
2003). 
The Brazilian's Patent Law and the Generic Medicine Law are like what Malerba (1999) defines 
as the two ways by which the institutions affect the sectoral system. The first is equivalent to a national 
institution that has different effects across the sector, depending of the features of technology and 
knowledge. The last is a sectoral institution which sectoral circumscribed implications 
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4. The Brazilian Pharmaceutical System of Innovation 
Despite the force and the scientific and technological capacity of the main companies of the 
sector, the pharmaceutical system of innovation depends crucially on elements placed beyond the 
company borders. 
The pharmaceutical industry is a very interesting case of sectoral system of innovation. It 
encompasses an ample variety of actors involved with research, production, consumption and 
regulation – companies, universities, public and private research institutions, financial institutions, 
regulatory authorities, consumers and hospitals (McKELVEY & ORSENIGO, 2001). Note that 
firms have a crucial hole in this system, but it goes well beyond them. Different countries have 
different pharmaceutical systems; and there are countries which do not even possess a 
pharmaceutical industry. In Brazil, however, the sectoral system of innovation reveals an important 
inconsistency between an active and strong public policy for health (with universal access and 
coverage) and very important fragilities in the industrial structures, mainly those related to the links 
along the innovative chain. Firms are an important part of this fragility. 
In this section will be presented a sectoral analysis based on the historical-institutional 
evolution of the Brazilian pharmaceutical industry starting at the decade of 1970 and in the 
activities done by some pharmaceutical laboratories in the period of 2000-2007. 
4.1. An environment without patent protection and with import restriction 
Foreign companies dominate the Brazilian pharmaceutical industry. In 1900, the participation of 
the foreign companies in the national market was of 2.1%, and struck 87.7% in 1980 (VALENTIM, 
2003), a gradual conquer that gained momentum during the 1950s and the 1960s, in the midst of 
nationalist reactions and political turmoil. Different policies, aiming, mainly, the internal development 
of the industry and the reduction of external dependence, were established. They were supposed to 
extend the population’s access to medicines. With this intent, was promulgated the Industrial Propriety 
Code (“Código de Propriedade Industrial”, by law 5.772, of 21.12.1971), preventing recognition of 
patents for pharmaceutical3 products, a measure intended to facilitate production and learning – at 
least, the ability to learn production of substances (active principles) and their “assemblies”. As one 
could not know at that moment, but we all now sadly recognize, the patents exemption could be 
required, but was absolutely insufficient to provide learning and developing capabilities. Having a large 
domestic market to develop their entrepreneurial strategies, most firms preferred to set very well 
developed marketing policies. Uneven income distribution creates at least three different markets – rich 
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consumers, poor consumers and public sector purchases. They were all large enough to fulfill most 
competition possibilities and to offer every firm some room. Income distribution and the relation it 
holds with competition and industrial dynamics should be taken into account if we intend to understand 
the differences between national cases such as Brazil and India, or USA and Japan. (See Tables A1, A2 
and A3 in the Annex). 
Until the end of the 80s, the direct control of prices by the Brazilian government in diverse 
sectors had a privileged place as an instrument of market organization and the orientation and 
articulation of the firms´ strategies. The domestic pharmaceutical industry did not escape this rule, 
having, during the years of 1970 and 1980, its prices susceptible to direct control regimes, established 
by the Federal Government by means of the Inter-ministry Council for Prices (“Conselho 
Interministerial de Preços”). This regulation meant to limit the price of medicines to certain levels, 
compatible with the Brazilian reality, so that the readjustments were, during great part of the time, 
below inflation4 (ROMANO & BERNARDO, 2001). 
The decade of 1980 was extremely turbulent for the Brazilian economy. Due to external crisis 
and to the scarcity of foreign currency, the government opted for the massive restriction of importations 
as a mean to alleviate the external constraints. The Act number 4, of 1984, took these restrictions to the 
pharmaceutical industry. The Federal Government established a market reserve for the pharmaceuticals 
that could be locally manufactured, forbidding imports and – this should be kept in mind – preventing 
competing projects, and so assuring mitigated competition. With the reduction of imports, stimulating 
vertical integration and diminishing the degree of external dependence related to the first stages of the 
pharmaceuticals chain (QUEIROZ & GONZÁLEZ, 2001). 
These measures intended to create conditions for the local pharmaceutical industry to engage in 
a process of technological upgrading in order to reach self-sufficiency in terms of production and, at a 
second moment, hypothetically, the ability to innovate. However, the local industry – both indigenous 
and foreign – was favored by market protection; and local firms were also favored by the reduction of 
costs, allowed by the patent withdrawal, simply to increase its profits, and not to make the investment 
in R&D that the State expected (QUEIROZ, 1993).  
 While Brazil did not recognize pharmaceutical patents for products and processes, there was a 
growth of the ‘similar medicines’5 category. The companies had enough margin to carry out 
considerable investments in marketing, creating differentiation for the trademark of their products.  
Frenkel (2001) defines two important characteristics of the medicines that differentiate them 
from other products and that, in the specific context of the Brazilian pharmaceutical industry, favored 
the predominance of the commercial logic front to the technological logic: i) the consumer is not 
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capable of evaluating diverse aspects of the quality of medicines, making it necessary for a specialized 
professional to certify it; and ii) even the demand for medicines depending on the patients, it is the 
doctors who prescribe them. In the absence of a recognized public certification trustworthy to the 
consumers, the reputation of the brand tends to be a key component in the determination of the 
purchase decisions. And the domestic laboratories possess an expressive number of sales 
representatives, responsible for using these characteristics to give a boost to their brands and, 
consequently, to create differentiation between products with similar or identical chemical substances. 
This practice created a kind of market reserve for their products, what, in turn, translated into extended 
profit margins.  
From the moment the commercial logic predominated over the technical-scientific logic, even if 
the latter should always be well anchored in the production and marketing assets, the de-linking 
between the actors and institutions that compose the innovation system becomes latent. The 
pharmaceutical firms and their laboratories should be the epicenter of innovation activities, but the 
institutional environment of Brazilian sectoral system was not capable of creating stimulations that 
made these actors demand technical-scientific inputs, as well as structuring strong and supported 
linkages between the remaining links of the innovation chain. The environment that public policies 
created to increase autonomy, development and learning failed to accomplish those goals; but 
facilitated firms structuring and a certain level of profitability. Price controls reinforced the logic of 
pursuing commodities and avoiding innovation.  
The Brazilian Science and Technology (S&T) System begun to strengthen at the 1930's, with 
the built of the Universidade de São Paulo, based on the Humboldtian values that merge research and 
teaching. The creation of the National Counsel of Technological and Scientific Development (Conselho 
Nacional de Desenvolvimento Científico e Tecnológico – CNPq) and of the Coordination for 
Improvement of Higher-Level Manpower (Coordenação de Aperfeiçoamento de Pessoal de Nível 
Superior – CAPES), at 1951, promoted a qualitative and quantitative leap in the Brazilian potential 
formation of human resources to attend the scientific and technological social needs. Another point that 
to be worthy of credit is the existence of a diversity of Public Research Institutes, notably in the 
agriculture sector – with the Campinas's Agronomic Institute (IAC) and the Brazilian Enterprise of 
Agropecuary Research (Embrapa), for example – and in the aerospace sector – with the National 
Spatial Research Institute (INPE) and the Aeronautics Technological Institute (ITA). Those institutes 
were the responsible by the good Brazilian international performance in those sectors. The birth of the 
Embraer, one of the Brazilian most successful enterprises in technological terms, is quite associated 
with the ITA's constitution. However, this model, in general terms, presented most successful at the 
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scientific production than at technological development terms. A possible explanation for that 
disconnection resides on the Brazilian industrialization model, which demanded few inputs for the local 
science and technology system.   
4.2. A set of institutional changes… 
The economic-institutional space of the health sector passed through deep transformations in 
Brazil, following, belatedly, the trend of most developed countries (GADELHA, 2003). Throughout the 
decade of 1990, several factors reflected on the behavior of the domestic pharmaceutical sector: we can 
detach the commercial and financial opening (1988-1993); the liberalization of prices (1991-1992); the 
launching of the macroeconomic stabilization plan (the Real, in 1993); the approval of the Patents Law 
(“Lei de Propriedade Industrial Brasileira”, in 1996); the creation of the generic medicine category 
(1999); the creation of the FDA-like “Agência Nacional de Vigilância Sanitária” (ANVISA) (1999) 
and the retake of the direct control on the prices of pharmaceuticals (2000). 
The process of easing import restrictions rendered difficult the growth and consolidation of the 
domestic production of active pharmaceutical ingredients (API). Additionally, in the decade of 1990, 
the increase of the finished medicine importations was of 1.304% and that of API intermediate 
pharmaceuticals, of 204% (QUEIROZ & GONZA'LES, 2001). (See Tables A4, A5, A6 and A7 in the 
Annex). 
After a long period of direct control exerted by the Inter-ministry Council for Prices, the 
pharmaceutical industry, at the beginning of the decade of 1990, started a period of free prices, 
including all the raw materials and all the pharmaceutical products for human use. The “Real Plan” 
contributed to changes in the structure and expectations about the potential of the Brazilian 
pharmaceutical market: on the one hand, the economic stability provided an increase of the units sold 
and generated an income-effect; and on the other hand, the exchange overvaluation strengthened the 
picture of the imports growth. (See Table A8 and A9 in the Annex). 
The liberalization of prices added to the market increase resulting from the new macroeconomic 
stability, positively modified the dynamics of the sector at the beginning of the decade, for it allowed 
the companies to regain the profit margin that was uneven since the 80s, a reflect of the elevated 
inflation rates of the Brazilian economy. The recovery of the margins and the resetting of the prices 
made it possible for companies to capitalize and invest, once the return perspectives increased. 
However, the high readjustments of prices drove the government to reinstate, in 2000, the price 
control, led by the Chamber for Regulation on Pharmaceuticals (“Câmara de Regulação do Mercado de 
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Medicamentos” – CMED), made up by several ministries, including Health, Finance, Industry and last 
but not least Justice. Since then, the readjustment calculations occur once a year and take in account the 
consumer price indexes, the productivity gains of the companies and the price variations between and 
within sectors. 
Even if the price control rolled by Federal Government, actually the Brazilian medicines 
consumption, in units, are practically at the same level of 1997, although, in values, has growth three 
times in Reais and two times in Dollars. (See Table A10 in the Annex). 
4.3. … and the emergency of a new competitive environment 
The Patents Law and the Generics Law were central in the unleashing of an ample and 
important set of changes in all the dimensions of the pharmaceutical industry and its competitive 
dynamics. These changes had accented impacts in the internal routines of the firms installed in Brazil, 
over all the locally-owned, domestic ones. 
In 1996, the Federal Government approved the Law 9,279/96, related to patents, fully operating 
in 1997 – because Brazil resigned voluntarily to the adaptation period permitted by the TRIPS 
agreement, signed in 1994. With this, new rules of patent property rights protection had been instituted, 
also to the pharmaceutical products. Since the launching of the Uruguay Round of GATT, intellectual 
propriety rights were forced into the negotiations, even if they were not directly related to the matter 
and they had an international organism in charge (WIPO). In this subject, most developed countries 
followed gracefully the leadership of the USA; and the shared vision of the “rich” became more and 
more part of mainstream, liberal followers in Brazil.  
Being completely insufficient to determine learning and capabilities development, patents 
exemption was undermined also among several other formed allies. From the moment pharmaceutical 
patents for products and processes started to be recognized on, it turned out to be impracticable to copy 
products that are still in the period of protection. And because Brazil voluntarily renounced to the five 
years grace period, domestic firms had to adapt fast. From then on, there was a growth of the 
investments in the improvement of the operational infrastructure, expansion of the firms’ industrial 
park and in the incorporation of new technologies. It’s appropriate to highlight that this change of 
position was fruit, in great measure, of the conjugation of this new legislation concerning Patents with 
the Generics Law. The new institutional elements made frail the competitive strategy of the companies 
who had constructed its market positions based mainly – if not exclusively – on commercial assets, as 
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trademarks and channels of distribution established by the relationship of companies with the medical 
class, the managers of the health system as well as drugstores and retailers. 
The Generics Law (“Lei do Medicamento Genérico”, Law 9,787/99) was created as an attempt 
to expand the accessibility to medicines in Brazil, being seen as a chance of growth by some of the 
domestic companies. The main difference between the generics and the alikes dwell in the requirement 
of tests for bioequivalence and relative bioavailability, necessary for the registration of the first6. 
The increasing participation of generic medicines disrupted the competition pattern of the 
pharmaceutical industry, shifting if from the commercial logic to the couple price and quality. Generics 
are supposed to be perfect substitutes for trademark medicines, including those originally created by 
the firms who discovered them by means of original research and associated efforts. They do not carry 
the high costs of R&D and their commercialization requires substantially lower expenses with 
marketing, because they are medications whose therapeutical qualities are already known and proven 
by agencies and specialized methods. As consequence, they arrive at lower prices to the consumers 
then trademark medications. 
The regulation of generic medicines made impracticable the strategy of concentrating all efforts 
on commercial assets, once these products do not possess fantasy name and must be put into sale only 
by the name of the active ingredient. This provoked an important change of the commercial strategies 
of companies: those firms that produce branded medicines (innovative or similar) spread their products 
to doctors, while the generic ones are promoted in drugstores and, when using the traditional ways 
(such as sales representatives), they emphasize the laboratory’s name (FRENKEL, 2001). 
4.3.1. The consolidation of generic medicines 
Beyond the intensification of competition and the treatments’ cost reduction, the entrance of 
generic medicines led to structural changes in the industry, with emphasis to the increased participation 
of some domestic companies. According to Pro-Generic Organization (2006), the four main companies 
of the segment are domestically owned – EMS Sigma Pharma, Medley Pharmaceutical Industry, Aché 
Laboratories and Eurofarma Laboratories. By capital origin, 74.6% of sales in the Brazilian generics 
market are made by domestic companies. 
The good performance in the generics’ class has stimulated the participation of the domestic 
laboratories in the total sales of the industry. In 2006 the Brazilian laboratories’ share was of 
approximately 43%. Leaning on the generic medicine commercialization, the main domestic companies 
have grown in terms of sales (Graph 1). The only exception to this rule came from the leading company 
 12 
within the group of domestic firms, too confident over its leadership to seize the opportunity offered by 
generics and even to appraise their potential effects. In 2000, almost forty years after its foundation, 
Aché presented the first red numbers in its history and started a process of organizational restructuring. 
This process involved, in 2005, the acquisition of one of the main generic medicine producers – 
Biosintética. If you can not beat them, join them.  
 
The Federal Government made huge efforts to put into effect the generics, with broad 
advertising campaigns broadcasted both in radio and television networks. According to Nishijima 
(2003), the State, through the requirement of the bioequivalence test, pointed to the market that the 
generic medicine stands as a high quality product. Moreover, the government investments on 
advertising of generics acted in similar way to those of the pharmaceutical companies with marketing. 
These factors were crucial to the enhancement of generics in the Brazilian pharmaceutical market. 
The generic medicines and the related policy modified the structure of the Brazilian 
pharmaceutical sector. In recent years, the local market awoke to the interest of foreign companies 
operating in the generics segment (Table 1). These companies, generally, buy raw materials from the 
matrix and/or international suppliers. 
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The domestic firms took advantage of the favorable environment to invest in new production 
units and the modernization of existing ones. Table 2 exemplifies investments done by indigenous 
companies, beyond showing an attention to the external market and the adequacy of the plants to the 
international requirements. To have access to these demanding markets, the Brazilian companies had to 
adapt to the respective local legislations that discipline the production and sale of generics. This 
includes remaking the formulations, approving the products and certificating the Brazilian plants in the 
sanitary control agencies of the United States and the European Union. 
 
It is quite different to supply medicines to less developed countries, predominant exportations 
markets of the domestic laboratories until here, where there isn’t an established industry, and the most 
developed, in which the competition is much more intense and has also different focus and scope. To 
penetrate with the generics in the first group of countries appears as an alternative to obtain scale 
economies, important because of the low profit margins of generic products. To sell medicine 
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manufactured in Brazil in consolidated markets such as U.S.A. and Europe can very be important for 
the growth and the consolidation of the domestic companies, but the challenges are far beyond given 
possibilities.  
The exportation of generic also is associated with research activities. To have a say in the 
international generics market, low costs are not enough . It is necessary to invest in research capable of 
resulting in medicines that, using different synthesis routes and different formulations, having 
bioequivalent clinical results, avoiding being simple copies of reference medicines. 
4.3.2. Induced efforts of innovation for the institutional changes 
As presented previously, when the strategy based in commercial efforts lost its momentum, the 
new regulatory landmark induced the local companies to include the technological capabilities and 
innovation in its strategic guideline. This new scene appeared as favorable to a larger interaction 
between actors of the Brazilian Pharmaceutical System of Innovation who had typically a more discrete 
performance. It marked the ascension of the universities, that historically had qualified staff and 
technical-scientific knowledge relevant to the pharmaceutical sector, but were little explored by local 
firms. A greater approach between research institutions and the industry has been observed recently, 
besides governmental and institutional actions in the course of successful innovative efforts. In the 
following paragraphs examples of this strategic positioning of the Brazilian pharmaceutical laboratories 
will be illustrated. 
In 2000, the São Paulo State Foundation for Science Promotion (Fundação de Amparo à 
Pesquisa do Estado de São Paulo , FAPESP) launched ten “Centros de Pesquisa, Inovação e Difusão” 
(CEPID). In the pharmaceutical area, deserves highlight the Center for Applied Toxicology (“Centro de 
Toxinologia Aplicada”, CAT), of the Butantan Institute. The objective of the CAT is to develop 
research on animals’ and microorganisms’ toxins, studying their properties to identify molecules that 
could be explored by the pharmaceutical industry in the creation of pharmaceuticals. The CAT 
congregates the abilities of the Butantan Institute, together with several research groups of the most 
important public universities. The projects developed since already generated patents registered in 
Brazil, U.S.A., Japan and the European Union. Amongst them, is a distinguished one deposited, in 
2001, in the Brazilian Patent Office (“Instituto Nacional de Propriedade Industrial”, INPI) referring to 
Evasin, an innovative drug with anti-hypertensive properties developed by the CAT from the jararaca 
(Bothrops Viperidae) poison. This project is carried out in a joint venture with the “Consórcio 
Farmacêutico Nacional” (COINFAR). Another high priority project concerns a protein analgesic 
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power called Enpak, obtained from the rattlesnake poison. It is an analgesic that has shown itself very 
powerful and, so far, did not present serious collateral effect. Also it is developed in partnership with 
the Coinfar. 
The Coinfar was born from an initiative of the Government of the State of São Paulo and 
FAPESP to try to generate local technologies from Brazilian biodiversity. It is a R&D joint-venture – 
which also acts in the consortia form – formed by three Brazilian pharmaceutical laboratories: Biolab-
Sanus, União Química (both belonging to the Castro Marques Group) and Biosintética (Aché). The 
initiative has the objective of operating as a technological and business-oriented platform for the 
companies that are part of it, developing projects of new chemical entities in therapeutical classes of 
international potential. However, its stake-holders stress that it faces several different difficulties and 
obstacles to increase the investments, to access capital for risky activities , in projects management in 
all phases, in the absorption of other technological projects, the internalization of R&D activities and, 
last but not least, the execution of pre-clinical trials in Brazil. 
The laboratories of the Coinfar also carry on parallel projects of research. In 2005, the 
Biosintética had a financing approved by the National Development Bank (“Banco Nacional de 
Desenvolvimento Econômico e Social”, BNDES) within Profarma7. The operation had the objective of 
expanding its R&D activities on new products and inputs for the pharmaceutical industry, over all in 
the dermatological line, in partnership with the PIC Chemical, which acts in the raw material segment 
for cosmetics, pharmaceuticals, nutritionals and phitotherapics. Biosintética stood out in the national 
scene for possessing about thirty patents in the international market. Also deserves emphasis the project 
to develop a line of products from Brazilian plants, through investments in university, and credit from 
the Brazilian Innovation Agency (“Financiadora de Estudos e Projetos”, FINEP) to extend its 
researches. 
Aché, the larger domestic pharmaceutical company, concentrates its efforts in R&D of its 
generics and prescription drugs in the biotechnology area, fortifying the endeavor that was lead by the 
Biosintética. The declared objective is to develop the studies that associate two or more molecules of 
already known drugs, called fixed associations. Between 1993 and 2003, the company developed four 
products from intelligent associations of different active ingredients in the same medicine. This type of 
innovation is important for the company, in first place, because it represents an income source that 
helps to support other innovation projects of higher risk. And, in second place, because it involves 
critical knowledge and the incremental innovations are important for the accumulation of competences. 
But it illustrates also the powerlessness of the company’s technological efforts.  
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In 2005, the Aché launched the anti-inflammatory Acheflan, a phytotherapic developed from 
the popular knowledge, with 100% national technology. The Acheflan passed through all the phases of 
scientific proof that a drug with a synthetic active ingredient must carry out. The studies for the 
development of the product took seven years and were lead in association with the Federal University 
of Santa Catarina (UFSC), with Unifesp, PUC-Campinas and the State University of Campinas 
(UNICAMP). Currently, the product is leader in the segment of dermal anti-inflammatories under 
medical prescription and presents good profit margins. Only the future will say if the success of this 
product is related more its therapeutic virtues or to the undeniable qualities of the company’s 
commercial assets, including a very well developed network with doctors and drugstores. 
The Biolab laboratory appealed to the BNDES for R&D financing. The intake was destined to 
support topic research of thirteen medicines, the creation of two new forms of presentation and the 
construction a semi-industrial plant for the development of new formulations. About the development 
of new products, Biolab-Sanus presented an innovative medicine for prophylaxis of Riots of the 
Closing of the Neural Pipe during the pregnancy, an illness that afflicts several thousand of babies each 
year, only in Brazil. Currently, the main treatment is with a combination of two medicines and the cost 
is about 2/3 of Brazilian minimum wage during the pregnancy. The company, requested from health 
autorithies (CMED) a price which is below the present cost of the treatment, while well above the 
production cost. The company argues that the new treatment would save more than R$ 6 millions each 
year for the public health system. The resolutions of CMED were conceived within a rather different 
context, to attend the necessity of the State for always cheaper medicines, not that of the innovative 
firms; that is why prices are linked to production costs, without R&D costs and innovation premium. 
The solution that the laboratory found to overcome the problem was to commercialize the product 
overseas and to import it back to Brazil, for the same price as the international market. There is, thus, a 
disarticulation between the Industrial Policy and the Health Policy of the Federal Government. But one 
could say that both, health and industrial policies, are still entrenched on the old fashioned way of 
thinking, even if both declare their engagement towards innovation. 
Biolab-Sanus, another local firm, in association with Eurofarma, also local, constituted 
Incrementha RD&I, a company for the development of new technological products and platforms, 
focusing projects of incremental innovation. The model adopted by Incrementha intends to internalize 
the abilities in regulation, patents, research and elaboration of protocols in clinical research. The team 
is formed by a doctor and twenty other employees specialized in key-areas for the development of new 
pharmaceutical products, such as marketing, patenting, regulatory, commercial evaluation, pharmo-
analysis development and clinical research. The lines of R&D count on the contribution of universities 
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and involve new combinations of already known drugs, new formulation of already known drugs and 
new molecules chemically related to existing drugs. 
Eurofarma is also involved in other projects. The company directs efforts to radical and 
incremental innovations, with the universities and research institutes playing an important role in the 
innovation process. About twelve researchers holding master and PhD grades currently work in the 
company in the areas of RD&I, with emphasis to the areas of biotechnology, molecular biology and 
pharmacology. The objective of Eurofarma is to go beyond the manufacturing of generics, and advance 
in more complex segments of the pharmaceutical industry. Also with partnerships withseveral different 
universities, the company intends to discover innovative products. Moreover, the company research 
team and their partners within the universities investigate on the Brazilian biodiversity to identify 
phytotherapic products and, by means of a technology transfer agreement with the American DevaTal, 
entered in the biotechnology area, counting on a pilot plant.The main project, amongst several on 
phytoterapics, refers to an oral product, with analgesic and anti-inflammatory action, obtained from the 
dry leaf extract of the Aleurites moluccana species. This project was initiated in 2001, in association 
with a research group from the University and, in 2007, the company applied for the patent on the 
extract. 
The domestic company Cristália is perhaps a distinguished case in terms of R&D activities and 
related industrial capabilities. This company stands out in the national scenario because it auto-supplies 
about 1/3 of the active principles used to produce its products –about 60 different molecules – an 
extraordinary fact in the pharmaceutical industry installed in the country – both local and foreign 
owned. Cristália received, recently, financial support from FINEP to internalize the production of 
pharmaceuticals. The company also established alliances with domestic research institutions, such as 
USP, state laboratory Far-Manguinhos, Institute of Technology in Pharmaceuticals, the Foundation 
Oswaldo Cruz, UFRJ, UFMG, Unicamp, Butantan Institute, amongst others. In 2004, Cristália received 
a patent from the United States Patent and Trade-Mark Office (USPTO), the North American official 
agency of industrial property registration, for the discovery of a new active ingredient when using an 
innovative technology to transform one old substance into an anesthetic and analgesic, with reduced 
collateral effect for patients. In 2006, Cristália received the patent for a compound for erectile 
dysfunction, from the USPTO. The product was launched in the market in 2007 and took six years to 
be developed, counting on financial support from FINEP and BNDES. Cristália engaged fifteen 
national research centers and universities to carry out the required clinical studies for the approval of 
the medicine. In 2007, the company licensed five patents from Unicamp, in the scope of the Innovation 
Law and had two projects approved in the economic subvention program, under the main subject 
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pharmaceuticals and medicines with focus in AIDS and hepatitis, one the main headings of the 
Subvention Program recently set up by federal government. The company R&D activities are 
developed by a team of about fifty people, including eight PhD holders, ten holding master´s degree 
and about thirty specialists. 
Chemical company Nortec is probably one exception in terms of the production of 
pharmaceutical active ingredients. With about 200 customers in Brazil abroad, it possesses the largest 
line of pharmaceuticals in Brazil, with 43 active ingredients being produced (and in the market) and 31 
more being development. 
Current leader of sales of the Brazilian pharmaceutical industry, the Group EMS-Sigma 
Pharma, set up the Research and Development Center, for the development of its formulations and tests 
of validation and stability in laboratorial and semi-industrial scale, counting, according to company, 
with about 200 people. It also works on analytical methods of equivalence and of new pharmaceutical 
presentations. In 2006, the group announced a partnership with the Italian company MonteResearch, 
specialized in pharmaceutical R&D. The objective of the agreement is to make the joint development 
of new pharmaceutical formulations. The companies began, in Brazil, to develop a clinical study with a 
new medicine against vaginal infections caused by fungus and bacteria. 
The examples presented here seem to point to an inflection of the strategy of the domestic 
industry when it comes to R&D activities. The investments in R&D by the industry were multiplied by 
more than 10 times between 1994 and 2003, from R$ 12.3 million to R$ 153 million in the period 
(REVISTA DA INDÚSTRIA FARMACÊUTICA, 2005). The culture of the clinical research is still in 
the initial phase of creation in the country and the domestic companies are only now becoming 
conscious about the importance of the pharmaceutical research. 
From the alternatives available to the domestic laboratories, stand out the incremental and 
phytotherapic research, which demand lower financial intakes and allow faster returns. The domestic 
segment of the industry may not yet have the required abilities to make innovative substances in large 
scale, but it can invest in incremental innovations and make me-too' s8 (case of the medicine for erectile 
malfunction of the Cristália Laboratory), to formulate fixed associations, and to find second uses for 
existing drugs. The understanding of the meanings of these innovations is subject to multiple 
understandings, but perhaps the most consistent interpretation shows that it is not a second category 
innovation, but innovation inside of a well established technological trajectory. It is perhaps the 
possible entry into a long neglected dimension of the pharmaceutical industry in Brazil.  
The delay of Brazil in this field is immense and requires, for its overcoming, a selective 
approach with regard to the niches in which it is possible to act. The Brazilian biodiversity represents – 
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according to many analysts – a great potential for radical innovations. But biodiversity is not enough to 
create innovative drugs; which depend heavily on new investments and broad and deep scientific 
knowledge.  
A second field refers to generic medicines of great interest to public health. Perhaps one of the 
main questions related to this matter relates to public choices in terms of costs versus effectiveness, and 
short term versus long term views. Some of the programs on public (universal) health, provided 
forcefully by the Constitution text approved in 1988, are expensive and depend heavily on choosing the 
first term in both pairs. Providing healthcare for every citizen is certainly the right thing to do, but once 
we admit that resources are scarce, it reduces the field of action.  
It is difficult to imagine that a new pharmaceutical industry can appear suddenly, after decades 
of performance based on copyist and lazy strategies, at least of the main – and most successful – 
protagonists. There are, however, diverse evidences that important changes are on the way. They seem 
to illustrate the process of sprouting and conformation of strategies capable of guaranteeing a certain 
capacity of innovation - even in incremental terms - to the domestic pharmaceutical industry. In short, 
one admits that the process in course is relevant mainly from the point of view of the trend that it can 
represent, where the modesty of the developed activities and the strong dependence with regard to the 
university research. 
5. Discussion and concluding remarks  
Brazil has traditionally been one of the largest pharmaceutical markets of the world (among the 
top ten), attracted investments from a whole bunch of multinational corporations, was able to develop 
scientific capabilities in the relevant areas of knowledge to conduct apparently quality research, it is 
supposed to have create also original discoveries – but it never achieved a drug discovery to move 
forward from the scientific discovery to the market. It is certainly true that the pharmaceutical industry 
is not just an industry like others. But conceiving and producing airplanes also cannot be considered an 
industry like most others, and Brazil possess now the 3rd or 4th largest airplanes manufacturer in the 
world. Even if the pharmaceutical industry has its own elements to be considered to explain the 
Brazilian disappointment in this field, the main reasons are certainly to be found elsewhere, and they 
seem to be mostly related to the Brazilian pharmaceutical system.  
The predominant strategy of the local industry until the middle of the 1990s was to copy 
medicines produced overseas and to acquire a favorable position in the market through massive efforts 
in marketing. Marketing, within the context of pharmaceuticals, is a quite large and diversified activity, 
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ranging from actions directed to main hospitals and doctors to tactics towards drugstores and 
salespeople. And some firms were active and smart enough to get into associations with foreign firms 
to commercialize their products in Brazil, charging a fee for their commercial assets. On the other 
hand, in this period, these same firms were not active at all in terms of conducting research of their own 
neither in cooperative ways, with universities and other public research organizations. The Brazilian 
Pharmaceutical System of Innovation, if we could define such an entity, was unfinished, immature, and 
underdeveloped. And the main fragility was not on the scientific side of the equation. 
The incorporation of the institutions to the analysis of the Brazilian pharmaceutical sector helps 
us on the understanding about the changes and the trajectories of development, incorporating social, 
political, scientific and institutional environments – both past and present. Institutions are capable of 
molding the action of the agents as well as they are capable of modifying their interactions. The 
approval both of the Patents Law and the Generic Medicine Law are two important building blocks of 
the Brazilian Pharmaceutical System of Innovation, and these two pillars are changing substantially the 
industrial structure and the competition dynamics. More and more, the firms are integrating both 
elements into their strategies, not only as a restriction, as it was the case of patents just after the 
approval of the Law, but much more as a constituent part of their actions and trajectories. At first, 
generics undermined and destabilized the leaders footholds, largely based on commercial assets; but the 
response was to adhere, even though on a displeased way. The firms which first seized the opportunity 
– for them immense – were able to jump in first and to build up strong positions based on generics.  
But domestic firms can not expect to survive and to growth based only on generics. The arrival 
of multinational companies producing generics, the limits of the first batch of products without patent 
protection, the exploration of legal mechanisms to extend the duration of the patents, and the larger 
complexity of some products – over all new, for which it is difficult to carry out the bioequivalence 
tests – all these factors limited the space for generics and contributed to diminish the performance of 
companies relying only on that family of products. Adding the fact that they are products with lower 
profit margins, it results that the survival of the manufacturers of generics in the medium run is far 
from assured. That is why companies’ perception was to give another, different step further. 
However, the adaptation and learning processes era slow and gradual, for new abilities are 
difficult to create and hard to modify. And this applies to a great extent to ‘old’, deeply rooted 
behaviors. It is obvious that the strategy to direct efforts to RD&I it is far from unanimous among the 
sector firms. There is still a considerable reluctance on the part of the companies’ stakeholders 
concerning a much more intense enrollment in such activities, full of uncertainties and risks. And the 
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short-term views, typically present on the old strategies, still contaminate the new ones, making 
technological choices much more restricted than they could otherwise be.  
It is possible to see both strategic alternatives – generic medicines and innovative products – as 
complementary. If we consider the hypothesis that the great expense in R&D is proportional to the cash 
flow of previous periods, the success domestic firms are getting with the generics will make them able 
to strengthen their financial muscles, adding to their R&D investments. Evidences exist, even if 
incipient, to confirm preliminarily this assertive. Additionally, as the companies strengthen their links 
with the innovation systems, they reinforce their qualifications in terms of R&D, openning the 
possibility of partnerships arrangements with universities, local and foreign companies, and research 
institutes – both public and private. Some examples pointed out here show the importance of 
partnerships for innovation in the pharmaceutical sector, for most domestic pharmaceutical companies 
simply did not had, until very recently, the means to conduct research on their own. They can rely on 
universities and PROs for that goal, but they still have very important limitations, relating to other 
stages, like clinical and pre-clinical trials or chemical synthesis. Companies abroad, who provide these 
services and that possess a series of chemical, biochemical, biotechnological and molecular biology 
expertise, can be assessed to full the gap, but one should perhaps start to recognize that the 
pharmaceutical industry and its innovation systems still have fissures and discontinuities. The 
pharmaceutical system of innovation, in Brazil, is still limited. 
 Adding to the value chain those stages with larger technological content is important to the 
survival of domestic companies in this segment. Moreover, it can also be an attraction factor for those 
multinationals companies, in search, for example, for competitive advantages. Such aggregation 
characterizes itself, therefore, as an essential condition to keep the competitiveness in the new market 
conditions provoked by the structural changes occurred in Brazil in the recent period. Despite 
production and innovation being distinct activities, they can be considered interdependent, and 
therefore the learning process inherent to the production activities represents an important input 
concerning the innovative activity. Initiatives in the molds of Coinfar, Incrementha, or the strategies of 
companies such as Cristália and Biolab, the linking between public and private research institutions, 
university and with federal financial institutions devoted to development, such as BNDES and FINEP, 
illustrate how the dynamics of all actors, ranging from the firms to academic, financial and regulatory 
spheres – were deeply modified.  
These examples keep alive the hopes for a more qualified domestic pharmaceutical industry and 
perhaps much more competitive in the international scenario. For such a change to happen it is 
necessary to go beyond structuring and strengthening the links between the university scientific 
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capabilities and the firms. As Rosenberg (1990) argued, for the firms to profit from scientific 
knowledge, they have to develop scientific capabilities of their own. The Brazilian Pharmaceutical 
System of Innovation has scientific qualification in the universities and has started to develop links – 
simple and complex – between those institutions and firms, but important fragilities still remain. They 
concern both public policies and the private sector strategies, still rooted in the old territory defined by 
import substitution and protection, along with price controls and marketing strategies. 
For the actors to exert their innovative potential, it is necessary that the environment favors the 
technological aspects as compared to the pure commercial logic. This seems to be indispensable for the 
development of local capacities and for the consolidation of the process that is – as the evidence 
suggest – in course. Individually, the next stage of development of the Brazilian Pharmaceutical 
System of Innovation will be the formation and consolidation of research teams internally to the 
companies or directly tied to its technological, industrial, patent and commercial strategies. The 
evidences and thoughts presented in this article are not enough to nullify the doubts that still exist about 
the strength and the effectiveness of this process, but to light up some important aspects and 
opportunities defined at present. The next years and the directions taken by firms and other members of 
the SSI should present us more definite elements and allow us to have much more unambiguous 
answers. Taken the risk of being too optimistic about our possibilities, we could perhaps finally direct 
our efforts to build-up a pharmaceutical structure and dynamic able to fulfill the best hopes of 
Brazilians´ health needs.  
 
Notes 
1 The article is mainly based on the monitoring and observation of the activities of the domestic 
pharmaceutical laboratories. The strategy and behavior of the multinational laboratories possesses a 
logic defined in another scale and they will not be analyzed. Additionally, the focus of the article 
concentrates in the firms’ strategies and it does not approach the insertion of the neglected illnesses, but 
the argument is compatible with a strong policy in this direction. 
2 Entity founded in 2001 that congregates the ten main generics industries in the country, corresponding 
to about 90% of this markets’ sales. 
3 truthfully, Brazil did not recognize patents for pharmaceutical products since the Decree Law 7,903, 
of 27 of August of 1945. 
4Accumulating imbalances, such as between 1984 and 1989, of 28% (QUEIROZ & GONZA'LES, 
2001). 
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5 Medicine copies that have propose the same action as the original product, however were not obliged 
to go through the tests that prove the same therapeutic action. 
6 In 2003, the Anvisa published 19 resolutions, determining the obligation to accomplish these tests for 
the new similars and those already in the market. 
7 Support Program for the Development of the Pharmaceutical Productive Chain, launched in 2004 and 
structured to contribute to the implementation of the industrial, technological and foreign commerce 
policies of the Federal Government. 
8 Are products launched later to the original and that possess molecular structure different enough of to 
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